Mesoblast Limited (ASX:MSB)

Market Cap	2.56B -9.9%
Revenue (ttm)	98.02M +1,053.2%
Net Income	-141.48M
EPS	-0.11
Shares Out	1.29B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,137,372
Average Volume	3,828,911
Open	2.060
Previous Close	1.985
Day's Range	2.040 - 2.080
52-Week Range	1.515 - 3.310
Beta	0.82
RSI	39.72
Earnings Date	May 25, 2026

About Mesoblast

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 81
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MSB

Financial Performance

In fiscal year 2025, Mesoblast's revenue was $17.20 million, an increase of 191.39% compared to the previous year's $5.90 million. Losses were -$102.14 million, 16.1% more than in 2024.

Financial numbers in USD